Q-omics provides the consensus-scored MIR1255A profile across patient tissues and cancer cell-line models. MIR1255A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR1255A is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR1255A RNA expression shows 7,034 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where MIR1255A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1255A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1255A survival associations across molecular data types. MIR1255A RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1255A RNA expression–survival associations across cancer types. High MIR1255A expression shows unfavorable associations in MESO, PAAD, BLCA, UCS, UVM and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify MESO as the clearest survival context for MIR1255A RNA expression.
This table summarizes MIR1255A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1255A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1255A shows lower tumor expression in BRCA, LUAD and LUSC and higher tumor expression in KIRC, PAAD and PRAD. The KIRC box plot shows higher MIR1255A RNA expression in tumor versus normal tissue (log2 FC = +0.193, t-test p = .015).
This table shows molecular features associated with MIR1255A in patient tissues and cancer cell lines. In patient samples, MIR1255A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
